{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:08:00Z","timestamp":1791986880604,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82151314"],"award-info":[{"award-number":["82151314"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372073"],"award-info":[{"award-number":["82372073"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Research Plan of SHDC","award":["SHDC2020CR2066B"],"award-info":[{"award-number":["SHDC2020CR2066B"]}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["202240031"],"award-info":[{"award-number":["202240031"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangci Clinical Technology and Innovation Program\uff08GCTIP\uff09of Ruijin Hospital","award":["GCQH2023061"],"award-info":[{"award-number":["GCQH2023061"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00259-025-07219-w","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T12:02:14Z","timestamp":1743768134000},"page":"3781-3791","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic value of [18F]fluorodeoxyglucose-PET\/MRI(CT) novel interpretation criteria (IMPeTUs) in multiple myeloma"],"prefix":"10.1007","volume":"52","author":[{"given":"Miao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tangjia","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyan","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongping","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuangyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Qing","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0493-2062","authenticated-orcid":false,"given":"Biao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"7219_CR1","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/s1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos M-V, Lonial S, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20:e302\u201312. https:\/\/doi.org\/10.1016\/s1470-2045(19)30309-2.","journal-title":"Lancet Oncol"},{"key":"7219_CR2","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/s1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348. https:\/\/doi.org\/10.1016\/s1470-2045(14)70442-5.","journal-title":"Lancet Oncol"},{"key":"7219_CR3","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/jco.22.00690","volume":"41","author":"J-Q Mi","year":"2023","unstructured":"Mi J-Q, Zhao W, Jing H, Fu W, Hu J, Chen L, et al. Phase II, Open-Label study of ciltacabtagene autoleucel, an Anti\u2013B-Cell maturation antigen chimeric antigen Receptor\u2013T-Cell therapy, in Chinese patients with relapsed\/refractory multiple myeloma (CARTIFAN-1). J Clin Oncol. 2023;41:1275\u201384. https:\/\/doi.org\/10.1200\/jco.22.00690.","journal-title":"J Clin Oncol"},{"key":"7219_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1001\/jamaoncol.2022.6834","volume":"9","author":"M Goldfinger","year":"2023","unstructured":"Goldfinger M, Shah N, Cooper DL. Chimeric antigen receptor T-Cell therapy for patients with multiple Myeloma\u2014A call for equal opportunity. JAMA Oncol. 2023;9:297\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2022.6834.","journal-title":"JAMA Oncol"},{"key":"7219_CR5","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1001\/jamaoncol.2021.3971","volume":"7","author":"D Kazandjian","year":"2021","unstructured":"Kazandjian D, Hill E, Dew A, Morrison C, Roswarski J, Korde N, et al. Carfilzomib, Lenalidomide, and dexamethasone followed by Lenalidomide maintenance for prevention of symptomatic multiple myeloma in patients with High-risk smoldering myeloma: A phase 2 nonrandomized controlled trial. JAMA Oncol. 2021;7:1678\u201385. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3971.","journal-title":"JAMA Oncol"},{"key":"7219_CR6","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","volume":"7","author":"O Landgren","year":"2021","unstructured":"Landgren O, Hultcrantz M, Diamond B, Lesokhin AM, Mailankody S, Hassoun H, et al. Safety and effectiveness of weekly Carfilzomib, Lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial. JAMA Oncol. 2021;7:862\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0611.","journal-title":"JAMA Oncol"},{"key":"7219_CR7","doi-asserted-by":"publisher","unstructured":"Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21\u201333. https:\/\/doi.org\/10.4065\/78.1.21","DOI":"10.4065\/78.1.21"},{"key":"7219_CR8","first-page":"28","volume":"23","author":"MT Drake","year":"2009","unstructured":"Drake MT. Bone disease in multiple myeloma. Oncol (Williston Park). 2009;23:28\u201332.","journal-title":"Oncol (Williston Park)"},{"key":"7219_CR9","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/ajh.25846","volume":"95","author":"FI Baffour","year":"2020","unstructured":"Baffour FI, Glazebrook KN, Kumar SK, Broski SM. Role of imaging in multiple myeloma. Am J Hematol. 2020;95:966\u201377. https:\/\/doi.org\/10.1002\/ajh.25846.","journal-title":"Am J Hematol"},{"key":"7219_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00259-020-05049-6","volume":"48","author":"B Jamet","year":"2021","unstructured":"Jamet B, Morvan L, Nanni C, Michaud AV, Bailly C, Chauvie S, et al. Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. Eur J Nucl Med Mol Imaging. 2021;48:1005\u201315. https:\/\/doi.org\/10.1007\/s00259-020-05049-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7219_CR11","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s00330-019-06469-1","volume":"30","author":"FE Lecouvet","year":"2020","unstructured":"Lecouvet FE, Boyadzhiev D, Collette L, Berckmans M, Michoux N, Triqueneaux P, et al. MRI versus (18)F-FDG-PET\/CT for detecting bone marrow involvement in multiple myeloma: diagnostic performance and clinical relevance. Eur Radiol. 2020;30:1927\u201337. https:\/\/doi.org\/10.1007\/s00330-019-06469-1.","journal-title":"Eur Radiol"},{"key":"7219_CR12","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1148\/radiol.2015141728","volume":"277","author":"C Bourillon","year":"2015","unstructured":"Bourillon C, Rahmouni A, Lin C, Belhadj K, Beaussart P, Vignaud A, et al. Intravoxel incoherent motion Diffusion-weighted imaging of multiple myeloma lesions: correlation with Whole-Body dynamic contrast Agent-enhanced MR imaging. Radiology. 2015;277:773\u201383. https:\/\/doi.org\/10.1148\/radiol.2015141728.","journal-title":"Radiology"},{"key":"7219_CR13","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1200\/JCO.2014.57.9961","volume":"33","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015;33:657\u201364. https:\/\/doi.org\/10.1200\/JCO.2014.57.9961.","journal-title":"J Clin Oncol"},{"key":"7219_CR14","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/s1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of 18 F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the international myeloma working group. Lancet Oncol. 2017;18:e206\u201317. https:\/\/doi.org\/10.1016\/s1470-2045(17)30189-4.","journal-title":"Lancet Oncol"},{"key":"7219_CR15","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","volume":"25","author":"R Walker","year":"2007","unstructured":"Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr., et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007;25:1121\u20138. https:\/\/doi.org\/10.1200\/JCO.2006.08.5803.","journal-title":"J Clin Oncol"},{"key":"7219_CR16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/RLU.0000000000003512","volume":"46","author":"N G\u00f3mez Le\u00f3n","year":"2021","unstructured":"G\u00f3mez Le\u00f3n N, Aguado Bueno B, Herreros P\u00e9rez M, Le\u00f3n Ram\u00edrez LF, Alegre A, Colletti PM, et al. Agreement between 18F-FDG PET\/CT and Whole-Body magnetic resonance compared with skeletal survey for initial staging and response at End-of-Treatment evaluation of patients with multiple myeloma. Clin Nucl Med. 2021;46:310\u201322. https:\/\/doi.org\/10.1097\/RLU.0000000000003512.","journal-title":"Clin Nucl Med"},{"key":"7219_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/bjh.17088","volume":"193","author":"E Hill","year":"2021","unstructured":"Hill E, Mena E, Morrison C, Dew A, Choyke P, Lindenberg L, et al. Diagnostic performance of 18 F-FDG-PET\/CT compared to standard skeletal survey for detecting bone destruction in smouldering multiple myeloma: time to move forward. Br J Haematol. 2021;193:125\u20138. https:\/\/doi.org\/10.1111\/bjh.17088.","journal-title":"Br J Haematol"},{"key":"7219_CR18","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3109\/10428194.2012.740559","volume":"54","author":"J Hillengass","year":"2013","unstructured":"Hillengass J, Landgren O. Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging early myeloma. Leuk Lymphoma. 2013;54:1355\u201363. https:\/\/doi.org\/10.3109\/10428194.2012.740559.","journal-title":"Leuk Lymphoma"},{"key":"7219_CR19","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.3390\/cancers12113155","volume":"12","author":"S Mul\u00e9","year":"2020","unstructured":"Mul\u00e9 S, Reizine E, Blanc-Durand P, Baranes L, Zerbib P, Burns R, et al. Whole-Body functional MRI and PET\/MRI in multiple myeloma. Cancers. 2020;12:3155. https:\/\/doi.org\/10.3390\/cancers12113155.","journal-title":"Cancers"},{"key":"7219_CR20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1200\/JCO.20.00386","volume":"39","author":"E Zamagni","year":"2021","unstructured":"Zamagni E, Nanni C, Dozza L, Carlier T, Bailly C, Tacchetti P, et al. Standardization of (18)F-FDG-PET\/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma. J Clin Oncol. 2021;39:116\u201325. https:\/\/doi.org\/10.1200\/JCO.20.00386.","journal-title":"J Clin Oncol"},{"key":"7219_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s00330-020-07177-x","volume":"31","author":"S Han","year":"2021","unstructured":"Han S, Woo S, Kim Y-I, Yoon DH, Ryu J-S. Prognostic value of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in newly diagnosed multiple myeloma: a systematic review and meta-analysis. Eur Radiol. 2021;31:152\u201362. https:\/\/doi.org\/10.1007\/s00330-020-07177-x.","journal-title":"Eur Radiol"},{"key":"7219_CR22","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s00259-015-3200-9","volume":"43","author":"C Nanni","year":"2016","unstructured":"Nanni C, Zamagni E, Versari A, Chauvie S, Bianchi A, Rensi M, et al. Image interpretation criteria for FDG PET\/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2016;43:414\u201321. https:\/\/doi.org\/10.1007\/s00259-015-3200-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7219_CR23","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.3390\/cancers12041030","volume":"12","author":"C Nanni","year":"2020","unstructured":"Nanni C. PET-FDG: impetus. Cancers. 2020;12:1030. https:\/\/doi.org\/10.3390\/cancers12041030.","journal-title":"Cancers"},{"key":"7219_CR24","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/s00259-017-3909-8","volume":"45","author":"C Nanni","year":"2018","unstructured":"Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, et al. Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2018;45:712\u20139. https:\/\/doi.org\/10.1007\/s00259-017-3909-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7219_CR25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13550-021-00846-y","volume":"11","author":"C Sachpekidis","year":"2021","unstructured":"Sachpekidis C, Merz M, Raab M-S, Bertsch U, Weru V, Kopp-Schneider A, et al. The prognostic significance of [18F]FDG PET\/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs). EJNMMI Res. 2021;11:100. https:\/\/doi.org\/10.1186\/s13550-021-00846-y.","journal-title":"EJNMMI Res"},{"key":"7219_CR26","first-page":"469","volume":"5","author":"C Sachpekidis","year":"2015","unstructured":"Sachpekidis C, Hillengass J, Goldschmidt H, Mosebach J, Pan L, Schlemmer HP, et al. Comparison of (18)F-FDG PET\/CT and PET\/MRI in patients with multiple myeloma. Am J Nucl Med Mol Imaging. 2015;5:469\u201378. eCollection 2015.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"7219_CR27","doi-asserted-by":"publisher","first-page":"6438","DOI":"10.1007\/s00330-023-09593-1","volume":"33","author":"B Jamet","year":"2023","unstructured":"Jamet B, Carlier T, Bailly C, Bodet-Milin C, Monnet A, Frampas E, et al. Hybrid simultaneous whole-body 2-[18F]FDG-PET\/MRI imaging in newly diagnosed multiple myeloma: first diagnostic performance and clinical added value results. Eur Radiol. 2023;33:6438\u201347. https:\/\/doi.org\/10.1007\/s00330-023-09593-1.","journal-title":"Eur Radiol"},{"key":"7219_CR28","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1007\/s00330-021-08388-6","volume":"32","author":"R Burns","year":"2022","unstructured":"Burns R, Mul\u00e9 S, Blanc-Durand P, Tofighi M, Belhadj K, Zerbib P, et al. Optimization of whole-body 2-[18F]FDG-PET\/MRI imaging protocol for the initial staging of patients with myeloma. Eur Radiol. 2022;32:3085\u201396. https:\/\/doi.org\/10.1007\/s00330-021-08388-6.","journal-title":"Eur Radiol"},{"key":"7219_CR29","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"P Moreau","year":"2017","unstructured":"Moreau P, Attal M, Caillot D, Macro M, Karlin L, et al. Prospective evaluation of magnetic resonance imaging and [18F]Fluorodeoxyglucose positron emission tomography-Computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol. 2017;35:2911\u20138. https:\/\/doi.org\/10.1200\/JCO.2017.72.2975.","journal-title":"J Clin Oncol"},{"key":"7219_CR30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1148\/radiol.2019181949","volume":"291","author":"C Messiou","year":"2019","unstructured":"Messiou C, Hillengass J, Delorme S, Lecouvet FE, Moulopoulos LA, Collins DJ, et al. Guidelines for acquisition, interpretation, and reporting of Whole-Body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS). Radiology. 2019;291:5\u201313. https:\/\/doi.org\/10.1148\/radiol.2019181949.","journal-title":"Radiology"},{"key":"7219_CR31","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1148\/radiol.13131529","volume":"271","author":"SL Giles","year":"2014","unstructured":"Giles SL, Messiou C, Collins DJ, Morgan VA, Simpkin CJ, West S, et al. Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma. Radiology. 2014;271:785\u201394. https:\/\/doi.org\/10.1148\/radiol.13131529.","journal-title":"Radiology"},{"key":"7219_CR32","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/s1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"key":"7219_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3324\/haematol.10554","volume":"92","author":"E Zamagni","year":"2007","unstructured":"Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92:50\u20135. https:\/\/doi.org\/10.3324\/haematol.10554.","journal-title":"Haematologica"},{"key":"7219_CR34","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1007\/s00277-020-04265-2","volume":"99","author":"C Mesguich","year":"2020","unstructured":"Mesguich C, Hulin C, Latrabe V, Lascaux A, Bordenave L, Hindie E, et al. Prospective comparison of 18-FDG PET\/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma. Ann Hematol. 2020;99:2869\u201380. https:\/\/doi.org\/10.1007\/s00277-020-04265-2.","journal-title":"Ann Hematol"},{"key":"7219_CR35","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1002\/cncr.26467","volume":"118","author":"D van Lammeren-Venema","year":"2012","unstructured":"van Lammeren-Venema D, Regelink JC, Riphagen II, Zweegman S, Hoekstra OS, Zijlstra JM. (1)(8)F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review. Cancer. 2012;118:1971\u201381. https:\/\/doi.org\/10.1002\/cncr.26467.","journal-title":"Cancer"},{"key":"7219_CR36","doi-asserted-by":"publisher","first-page":"20130464","DOI":"10.1259\/bjr.20130464","volume":"87","author":"F Fraioli","year":"2014","unstructured":"Fraioli F, Punwani S. Clinical and research applications of simultaneous positron emission tomography and MRI. Br J Radiol. 2014;87:20130464. https:\/\/doi.org\/10.1259\/bjr.20130464.","journal-title":"Br J Radiol"},{"key":"7219_CR37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","volume":"130","author":"L Rasche","year":"2017","unstructured":"Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017;130:30\u20134. https:\/\/doi.org\/10.1182\/blood-2017-03-774422.","journal-title":"Blood"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07219-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07219-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07219-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T01:10:44Z","timestamp":1754356244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07219-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["7219"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07219-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"22 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants were conducted in accordance with the ethical guidelines of the 1964 Helsinki Declaration and national regulations. The prospective study was approved by the Research Ethics Committee of Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine (Approval No. 2019-10).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from each individual participating in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Author Biao Li is an Associate Editor of this journal (European Journal of Nuclear Medicine and Molecular Imaging). Author Kuangyu Shi is also an Associate Editor of this journal. The other authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}